The role of pro-drug therapy in the treatment of cancer

M. J. Ferguson, Fazle Ahmed, J. Cassidy

    Research output: Contribution to journalArticle

    21 Citations (Scopus)

    Abstract

    The administration of anti-cancer agents is currently associated with significant toxicity and lack of tumour specificity. Prodrugs are being designed to favourably alter the therapeutic index of these agents by improving their efficacy and reducing toxicity Progress in the development of prodrugs including the cytotoxic agents most commonly used in cancer treatments namely 5-fluorouracil (5-FU), the anthracyclines, paclitaxel and platinum will be described. Many of these agents are at an early stage of development: however, this article will also describe those which have already made an impact in the clinic. It is likely that future improvements in care will come from refinement of the drugs already well established in clinical practice. In addition, this technology could be applied to novel agents with alternative cellular targets such as those involved in angiogenesis or in conferring metastatic potential. Thus, lessons learned with standard drugs may be applicable across a wider spectrum of therapeutics. (C) 2001 Harcourt Publishers Ltd.

    Original languageEnglish
    Pages (from-to)225-232
    Number of pages7
    JournalDrug Resistance Updates
    Volume4
    Issue number4
    DOIs
    Publication statusPublished - 2001

    Keywords

    • PROSTATE-SPECIFIC ANTIGEN
    • L-LEUCYL-DOXORUBICIN
    • PRELIMINARY IN-VITRO
    • ANTITUMOR-ACTIVITY
    • POLYETHYLENE-GLYCOL
    • PHASE-I
    • N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMERS
    • POLY(ETHYLENE GLYCOL)
    • PACLITAXEL CONJUGATE
    • 5-FLUOROURACIL 5-FU

    Cite this